Inhibition of B cell activation following in vivo co-engagement of B cell antigen receptor and Fcγ receptor IIb in non-autoimmune-prone and SLE-prone mice

Edwards, 2004, Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis, N. Engl. J. Med., 350, 2572, 10.1056/NEJMoa032534 Stohl, 2012, Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus, Arthritis Rheum., 64, 2328, 10.1002/art.34400 Dall’Era, 2007, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus, Arthritis Rheum., 56, 4142, 10.1002/art.23047 Ginzler, 2012, Atacicept in Combination with MMF and Corticosteroids in Lupus Nephritis: Results of a Prematurely Terminated Trial, Arthritis Res Ther, 14, R33, 10.1186/ar3738 Isenberg, 2015, Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (APRIL-SLE randomised trial), Ann. Rheum. Dis., 74, 2006, 10.1136/annrheumdis-2013-205067 Mysler, 2013, Efficacy and safety of ocrelizumab in active proliferative lupus nephritis: results from a randomized, double-blind, phase III study, Arthritis Rheum., 65, 2368, 10.1002/art.38037 Roberts, 2015, Immunoglobulin G replacement for the treatment of infective complications of rituximab-associated hypogammaglobulinemia in autoimmune disease: a case series, J. Autoimmun., 57, 24, 10.1016/j.jaut.2014.11.004 Carson, 2009, Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project, Blood, 113, 4834, 10.1182/blood-2008-10-186999 Fredericks, 2014, A case of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab, Lupus, 23, 711, 10.1177/0961203314524292 Nimmerjahn, 2008, Fc γ receptors as regulators of immune responses, Nat. Rev. Immunol., 8, 34, 10.1038/nri2206 Chu, 2008, Inhibition of B cell receptor-mediated activation of primary human B cells by coengagement of CD19 and FcγRIIb with Fc-engineered antibodies, Mol. Immunol., 45, 3926, 10.1016/j.molimm.2008.06.027 Depoil, 2008, CD19 is essential for B cell activation by promoting B cell receptor-antigen microcluster formation in response to membrane-bound ligand, Nat. Immunol., 9, 63, 10.1038/ni1547 Szili, 2014, Sármay Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19, mAbs, 6, 991, 10.4161/mabs.28841 Horton, 2011, Antibody-mediated coengagement of FcγRIIb and B cell receptor complex suppresses humoral immunity in, systemic lupus erythematosus Journal of Immunology, 186, 4223 Mackay, 2006, Selective dysregulation of the FcγIIB receptor on memory B cells in SLE, J. Exp. Med., 203, 2157, 10.1084/jem.20051503 Su, 2007, Expression profile of FcγRIIB on leukocytes and its dysregulation in systemic lupus erythematosus, J. Immunol., 178, 3272, 10.4049/jimmunol.178.5.3272 Zhao, 2020, Bispecific antibodies for autoimmune and inflammatory diseases: clinical progress to date, BioDrugs, 34, 111, 10.1007/s40259-019-00400-2 Morel, 1996, Production of congenic mouse strains carrying genomic intervals containing SLE-susceptibility genes derived from the SLE-prone NZM2410 strain, Mamm. Genome, 7, 335, 10.1007/s003359900098 Markel, 1997, Theoretical and empirical issues for marker-assisted breeding of congenic mouse strains, Nat. Genet., 17, 280, 10.1038/ng1197-280 Waters, 2001, NZM2328: a new mouse model of systemic lupus erythematosus with unique genetic susceptibility loci, Clin. Immunol., 100, 372, 10.1006/clim.2001.5079 Morel, 1997, Functional dissection of systemic lupus erythematosus using congenic mouse strains, J. Immunol., 158, 6019, 10.4049/jimmunol.158.12.6019 Morel, 2001, The major murine systemic lupus erythematosus susceptibility locus, Sle1, is a cluster of functionally related genes, Proc. Natl. Acad. Sci. U.S.A., 98, 1787, 10.1073/pnas.98.4.1787 Moore, 2011, A novel bispecific antibody format enables simultaneous bivalent and monovalent co-engagement of distinct target antigens, mAbs, 3, 546, 10.4161/mabs.3.6.18123 Rolink, 1996, A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors, J. Exp. Med., 183, 187, 10.1084/jem.183.1.187 Jacob, 2011, B cell and BAFF dependence of IFN-α-exaggerated disease in systemic lupus erythematosus-prone NZM 2328 mice, J. Immunol., 186, 4984, 10.4049/jimmunol.1000466 Jacob, 2012, Dispensability of APRIL to the development of systemic lupus erythematosus in NZM 2328 mice, Arthritis Rheum., 64, 1610, 10.1002/art.33458 Tutt, 2015, Development and characterization of monoclonal antibodies specific for mouse and human Fcγ receptors, J. Immunol., 195, 5503, 10.4049/jimmunol.1402988 Dutertre, 2008, A novel subset of NK cells expressing high levels of inhibitory FcγRIIB modulating antibody-dependent function, J. Leukoc. Biol., 84, 1511, 10.1189/jlb.0608343 Jacob, 2015, Differential development of systemic lupus erythematosus in NZM 2328 mice deficient in discrete pairs of BAFF receptors, Arthritis & Rheumatology, 67, 2523, 10.1002/art.39210 Jacob, 2006, Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand Mixed 2328 mice deficient in BAFF, J. Immunol., 177, 2671, 10.4049/jimmunol.177.4.2671 Agrawal, 2009, Deficiency of type I IFN receptor in lupus-prone New Zealand Mixed 2328 mice decreases dendritic cell numbers and activation and protects from disease, J. Immunol., 183, 6021, 10.4049/jimmunol.0803872 Jacob, 2009, Accelerated pathological and clinical nephritis in systemic lupus erythematosus-prone New Zealand Mixed 2328 mice doubly deficient in TNF receptor 1 and TNF receptor 2 via a Th17-associated pathway, J. Immunol., 182, 2532, 10.4049/jimmunol.0802948 Jacob, 2013, Development of systemic lupus erythematosus in NZM 2328 mice in the absence of any single BAFF receptor, Arthritis Rheum., 65, 1043, 10.1002/art.37846 Navarra, 2011, Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial, Lancet, 377, 721, 10.1016/S0140-6736(10)61354-2 Furie, 2011, A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus, Arthritis Rheum., 63, 3918, 10.1002/art.30613 Merrill, 2016, Ann. Rheum. Dis., 75, 332, 10.1136/annrheumdis-2015-207654 Stohl, 2017, Efficacy and Safety of Subcutaneous Belimumab in Systemic Lupus Erythematosus: A Randomized, Double-Blind, Placebo-Controlled, 52-week Study, Arthritis Rheumatol., 69, 1016, 10.1002/art.40049 Zhang, 2018, A Pivotal Phase III, Randomised, Placebo-Controlled Study of Belimumab in Patients with Systemic Lupus Erythematosus Located in China, Japan and South Korea, Ann. Rheum. Dis., 77, 355, 10.1136/annrheumdis-2017-211631 Furie, 2020, Two-year, randomized, controlled trial of belimumab in lupus nephritis, N. Engl. J. Med., 383, 1117, 10.1056/NEJMoa2001180 Gong, 2005, Importance of cellular microenvironment and circulatory dynamics in B cell immunotherapy, J. Immunol., 174, 817, 10.4049/jimmunol.174.2.817 Thompson, 2000, BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population, J. Exp. Med., 192, 129, 10.1084/jem.192.1.129 Gross, 2001, TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease: impaired B cell maturation in mice lacking BLyS, Immunity, 15, 289, 10.1016/S1074-7613(01)00183-2 Ganesan, 2012, FcγRIIb on liver sinusoidal endothelium clears small immune complexes, J. Immunol., 189, 4981, 10.4049/jimmunol.1202017 Bolland, 2000, Spontaneous autoimmune disease in FcγRIIB-deficient mice results from strain-specific epistasis, Immunity, 13, 277, 10.1016/S1074-7613(00)00027-3 McGaha, 2005, Restoration of tolerance in lupus by targeted inhibitory receptor expression, Science, 307, 590, 10.1126/science.1105160 Brownlie, 2008, Distinct cell-specific control of autoimmunity and infection by FcγRIIb, J. Exp. Med., 205, 883, 10.1084/jem.20072565 Su, 2007, Expression profile of FcγRIIB on leusocytes and its dysregulation in systemic lupus erythematosus, J. Immunol., 178, 3272, 10.4049/jimmunol.178.5.3272 Floto, 2005, Loss of function of a lupus-associated FcγRIIb polymorphism through exclusion from lipid rafts, Nat. Med., 11, 1056, 10.1038/nm1288 Chu, 2014, Suppression of rheumatoid arthritis B Cells by XmAb5871, an anti-CD19 antibody that coengages B cell antigen receptor complex and Fcγ receptor IIb inhibitory receptor, Arthritis & Rheumatology, 66, 1153, 10.1002/art.38334